-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
<>/* Style Definitions */ span.
In January this year, the study has completed the enrollment of the first patient in China.
Based on the clinical trial results obtained in Australia and China, the US FDA approved KN046 to directly enter Phase II clinical trials in the United States, and granted KN046 the orphan drug designation for the treatment of thymic epithelial tumors in September 2020
On December 12, 2019, the company was listed on the main board of the Hong Kong Stock Exchange, stock code: 9966
The company's product pipeline includes 15 highly differentiated anti-tumor drug candidates with independent intellectual property rights, mainly double antibodies, and a Covid-19 multifunctional antibody, four of which are in China, the United States, Japan, and Australia It is in clinical phase I-III
The company is committed to building an internationally leading, multi-dimensional drug development and industrialization platform, focusing on multifunctional biomacromolecule new drugs, benefiting patients in China and around the world
The ENREACH-Thymic enrolled patients is a phase II, open, multi-center registered clinical study to evaluate the effectiveness, safety and tolerability of KN046 in patients with advanced thymic cancer
.
In January this year, the study has completed the enrollment of the first patient in China.
About KN046
KN046 is a PD-L1/CTLA-4 bispecific antibody independently developed by Corning Jereh.
Its innovative design includes the fusion of CTLA-4 and PD-L1 single domain antibodies with different mechanisms; it can be targeted to enrich in PD- The tumor microenvironment with high expression of L1 and the elimination of Treg that inhibit tumor immunity
.
KN046 has carried out nearly 20 clinical trials of different stages covering more than 10 types of tumors such as non-small cell lung cancer, thymic cancer, pancreatic cancer, liver cancer, esophageal squamous cell carcinoma, and triple-negative breast cancer in Australia, the United States and China.
The advantage of survival benefit
.
Based on the clinical trial results obtained in Australia and China, the US FDA approved KN046 to directly enter Phase II clinical trials in the United States, and granted KN046 the orphan drug designation for the treatment of thymic epithelial tumors in September 2020
About Corning Jerry
Corning Jereh Biopharmaceuticals focuses on the research and development, production and commercialization of innovative anti-tumor drugs
.
On December 12, 2019, the company was listed on the main board of the Hong Kong Stock Exchange, stock code: 9966
Corning Jereh Biopharmaceuticals has a discovery, R&D, and manufacturing platform for the entire industry chain in bispecific antibody and protein engineering
.
The company's product pipeline includes 15 highly differentiated anti-tumor drug candidates with independent intellectual property rights, mainly double antibodies, and a Covid-19 multifunctional antibody, four of which are in China, the United States, Japan, and Australia It is in clinical phase I-III
The company has multiple technical platforms with independent intellectual property rights such as heterodimers and hybrid antibodies, and large-scale production capabilities that comply with China, the United States and the European Union cGMP standards, and have passed a complete quality system including multiple audits of the European Union QP.
.
The company is committed to building an internationally leading, multi-dimensional drug development and industrialization platform, focusing on multifunctional biomacromolecule new drugs, benefiting patients in China and around the world
